National Pension Service Has $191.84 Million Position in Bristol-Myers Squibb (NYSE:BMY)

National Pension Service raised its position in Bristol-Myers Squibb (NYSE:BMY - Free Report) by 2.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,738,757 shares of the biopharmaceutical company's stock after buying an additional 79,191 shares during the quarter. National Pension Service owned about 0.18% of Bristol-Myers Squibb worth $191,836,000 at the end of the most recent reporting period.

Other hedge funds have also recently made changes to their positions in the company. Addison Advisors LLC lifted its holdings in Bristol-Myers Squibb by 6.6% in the third quarter. Addison Advisors LLC now owns 3,120 shares of the biopharmaceutical company's stock valued at $181,000 after acquiring an additional 192 shares during the period. Symphony Financial Ltd. Co. raised its stake in Bristol-Myers Squibb by 4.1% during the third quarter. Symphony Financial Ltd. Co. now owns 4,980 shares of the biopharmaceutical company's stock worth $288,000 after purchasing an additional 194 shares during the period. Blue Bell Private Wealth Management LLC raised its stake in Bristol-Myers Squibb by 61.5% during the third quarter. Blue Bell Private Wealth Management LLC now owns 525 shares of the biopharmaceutical company's stock worth $30,000 after purchasing an additional 200 shares during the period. AMG National Trust Bank raised its stake in Bristol-Myers Squibb by 1.0% during the third quarter. AMG National Trust Bank now owns 19,685 shares of the biopharmaceutical company's stock worth $1,143,000 after purchasing an additional 201 shares during the period. Finally, Westside Investment Management Inc. raised its stake in shares of Bristol-Myers Squibb by 2.9% in the 4th quarter. Westside Investment Management Inc. now owns 7,156 shares of the biopharmaceutical company's stock valued at $367,000 after acquiring an additional 204 shares during the period. 76.41% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

BMY has been the topic of several analyst reports. Barclays dropped their price target on shares of Bristol-Myers Squibb from $51.00 to $43.00 and set an "equal weight" rating on the stock in a research note on Friday, April 26th. StockNews.com lowered shares of Bristol-Myers Squibb from a "strong-buy" rating to a "buy" rating in a research note on Monday, April 15th. Wells Fargo & Company boosted their price target on shares of Bristol-Myers Squibb from $51.00 to $52.00 and gave the stock an "equal weight" rating in a research report on Thursday, April 18th. Redburn Atlantic downgraded shares of Bristol-Myers Squibb from a "buy" rating to a "neutral" rating and dropped their target price for the stock from $77.00 to $54.00 in a report on Tuesday, February 6th. Finally, BMO Capital Markets dropped their target price on shares of Bristol-Myers Squibb from $55.00 to $48.00 and set a "market perform" rating on the stock in a research report on Friday, April 26th. One investment analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat, the company has an average rating of "Hold" and an average target price of $60.00.

Bristol-Myers Squibb Price Performance

BMY traded up $1.08 on Thursday, hitting $44.75. 10,774,480 shares of the stock were exchanged, compared to its average volume of 15,686,079. Bristol-Myers Squibb has a 12 month low of $43.33 and a 12 month high of $69.10. The business has a 50-day moving average of $49.96 and a two-hundred day moving average of $50.43. The company has a debt-to-equity ratio of 2.99, a current ratio of 1.11 and a quick ratio of 0.99. The firm has a market capitalization of $90.71 billion, a price-to-earnings ratio of -14.43, a PEG ratio of 14.82 and a beta of 0.45.

Bristol-Myers Squibb (NYSE:BMY - Get Free Report) last posted its earnings results on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping analysts' consensus estimates of ($4.53) by $0.13. The firm had revenue of $11.87 billion during the quarter, compared to analysts' expectations of $11.45 billion. Bristol-Myers Squibb had a negative net margin of 13.50% and a positive return on equity of 8.83%. The business's revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.05 earnings per share. Sell-side analysts forecast that Bristol-Myers Squibb will post 0.59 EPS for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Wednesday, May 1st. Stockholders of record on Friday, April 5th were paid a $0.60 dividend. This represents a $2.40 annualized dividend and a dividend yield of 5.36%. The ex-dividend date was Thursday, April 4th. Bristol-Myers Squibb's dividend payout ratio is currently -77.42%.

About Bristol-Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.